全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 201530-41-8 |
|---|---|---|---|
| 分子式 | C21H15N3O4 | 纯度 | 99% |
| 分子量 | 373.36 | 货号 | abs47027705 |
| 规格 | 2mg | 供货周期 | 现货 |
| 主要用途 | use is to reduce chronic iron overload | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Deferasirox 201530-41-8
| 产品描述 | |
| 描述 | Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. |
| 纯度 | 99% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 地拉罗司；ICL 670 |
| 外观 | 白色至淡黄色性粉末 |
| 可溶性/溶解性 | DMSO : 69 mg/mL (184.8 mM) Ethanol : 2 mg/mL (5.35 mM) |
| 生物活性 | |
| 靶点 | iron |
| In vitro(体外研究) | In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner. |
| In vivo(体内研究) | The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy. |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | CancerCancer Metabolism CancerTumor immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：